Neurocrine Biosciences ((NBIX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Neurocrine Biosciences is conducting a long-term study titled ‘A Long-Term, Open-Label Study to Assess the Safety and Tolerability of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD).’ The study aims to evaluate the safety and tolerability of NBI-1065845 when used alongside standard treatments for MDD, a significant mental health condition affecting millions globally.
The intervention being tested is NBI-1065845, an experimental drug administered orally once a day. It is designed to complement existing treatments for MDD, potentially offering a new avenue for patients who do not fully respond to current therapies.
This Phase 3 study is interventional, with a single-group assignment and no masking, focusing on treatment as its primary purpose. The open-label design allows all participants and researchers to know which treatment is being administered, streamlining the assessment of the drug’s long-term safety.
The study began on April 16, 2025, with the primary completion and estimated completion dates yet to be announced. The last update was submitted on July 29, 2025, indicating ongoing recruitment and progress.
This study could influence Neurocrine Biosciences’ stock performance positively if results show favorable outcomes, potentially boosting investor confidence. The success of NBI-1065845 could also impact the competitive landscape in the MDD treatment market, where effective adjunctive therapies are in demand.
The study is currently recruiting, with further details available on the ClinicalTrials portal.